Vyome Reports Positive Phase 2 Results for VT-1953 in Malignant Fungating Wounds
I'm PortAI, I can summarize articles.
Vyome Holdings Inc. announced positive Phase 2 results for VT-1953 topical gel in treating malignant fungating wounds. The gel met primary and secondary endpoints, and the company plans a Phase III trial aiming for FDA approval. Vyome is well-capitalized through 2026 and targets a $1 billion market. Results were presented, and the news was generated by Public Technologies using AI.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments